Drug intelligence / Profile preview

radioiodinated T84.66 minibody

Development stage
Unknown
Lead developer
Beckman Research Institute at the City of Hope
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

**Radioiodinated T84.66 minibody** is an investigational anti-carcinoembryonic antigen imaging radiopharmaceutical based on an approximately 80 kDa chimeric recombinant antibody fragment. The construct contains a single-chain variable fragment fused to a human IgG1 CH3 domain and forms a bivalent dimer that binds carcinoembryonic antigen-related cell adhesion molecule 5. It has been labeled with iodine-123 for gamma-camera and SPECT imaging in patients with colorectal cancer and iodine-124 for PET imaging in preclinical CEA-positive tumor xenograft models. Its intermediate molecular size supports rapid tumor localization and blood clearance, improving tumor-to-background contrast for detection of CEA-expressing lesions. ([aacrjournals.org](https://aacrjournals.org/clincancerres/article/10/15/5014/182111/Pilot-Trial-Evaluating-an-123I-Labeled-80))

Other names
123I-T84.66 minibody124I-T84.66 minibodycT84.66 minibodycT-84.66 minibodycT 84.66 minibodyradioiodinated anti-CEA minibodyT84.66 minibodyT-84.66 minibodyT 84.66 minibody
02

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)

Beyond the preview

Go deeper on radioiodinated T84.66 minibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on radioiodinated T84.66 minibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call